Article Text

Download PDFPDF
Individual-level and country-level socioeconomic determinants of disease outcomes in SpA: multinational, cross-sectional study (ASAS-COMOSPA)
  1. Polina Putrik1,
  2. Sofia Ramiro2,
  3. Anna Moltó3,
  4. Andras P Keszei4,
  5. Sam Norton5,
  6. Maxime Dougados3,
  7. Désirée van der Heijde6,
  8. Robert B M Landewé6,7,
  9. Annelies Boonen1
  1. 1 Rheumatology, Maastricht University Medical Center and Care and Public Health Research Institute (CAPHRI), Maastricht University, Maastricht, The Netherlands
  2. 2 Rheumatology, Leiden University Medical Center, Leiden, The Netherlands
  3. 3 Rheumatology Department, Cochin Hospital, Assistance Publique-Hôpitaux de Paris, and INSERM (U1153): Clinical Epidemiology and Biostatistics, PRES Sorbonne Paris-Cité, Paris Descartes University, Paris, France
  4. 4 Medical Informatics, Uniklinik RWTH Aachen University, Aachen, Germany
  5. 5 Academic Rheumatology Department, King’s College London, London, UK
  6. 6 Amsterdam Rheumatology & Immunology Center, Amsterdam, The Netherlands
  7. 7 Rheumatology, Zuyderland Medical Center, Heerlen, The Netherlands
  1. Correspondence to Dr Polina Putrik, Rheumatology, Maastricht University Medical Center and Care and Public Health Research Institute (CAPHRI), Maastricht University, Maastricht 6202 AZ, The Netherlands; polina.putrik{at}gmail.com

Footnotes

  • Handling editor Josef S Smolen

  • Contributors AB, RBML and DvdH have conceived the idea. PP has performed the analyses and drafted the first version. APK and SN provided statistical advice. All authors have contributed to the analyses and interpretation, as well as read and approved the final version of the manuscript.

  • Funding The COMOSPA study was conducted with the financial support from AbbVie, Pfizer and UCB, which provided an unrestricted grant to ASAS to fund the study. The funders did not have any role in the design or conduct of the study. This ancillary study did not receive any funding, and the sponsors of COMOSPA did not have any interference with this current study.

  • Competing interests None declared.

  • Patient consent for publication Obtained.

  • Ethics approval All local ethics committees approved the COMOSPA study protocol and all patients gave their informed consent upon participation.

  • Provenance and peer review Not commissioned; externally peer reviewed.

View Full Text

Statistics from Altmetric.com

Footnotes

  • Handling editor Josef S Smolen

  • Contributors AB, RBML and DvdH have conceived the idea. PP has performed the analyses and drafted the first version. APK and SN provided statistical advice. All authors have contributed to the analyses and interpretation, as well as read and approved the final version of the manuscript.

  • Funding The COMOSPA study was conducted with the financial support from AbbVie, Pfizer and UCB, which provided an unrestricted grant to ASAS to fund the study. The funders did not have any role in the design or conduct of the study. This ancillary study did not receive any funding, and the sponsors of COMOSPA did not have any interference with this current study.

  • Competing interests None declared.

  • Patient consent for publication Obtained.

  • Ethics approval All local ethics committees approved the COMOSPA study protocol and all patients gave their informed consent upon participation.

  • Provenance and peer review Not commissioned; externally peer reviewed.

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.